ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Data challenge explores inflammation s hidden role in heart disease

(NewMediaWire) - June 11, 2025 - DALLAS — Elevated high-sensitivity C-reactive protein (hsCRP) is a marker of inflammation linked to increased risk of heart attacks, strokes and other forms of cardiovascular disease, even in healthy individuals with normal cholesterol. Awareness of elevated hsCRP can help identify people at increased risk and enable appropriate treatment that may improve their health outcomes.

To learn more about how hsCRP impacts individuals, the American Heart Association®, a global force changing the future of health for all, today announced the launch of the Systemic Inflammation Data Challenge, a new research initiative that will leverage advanced data science to explore how inflammation contributes to cardiovascular disease.

“The Systemic Inflammation Data Challenge aims to drive new understanding and inspire better, more equitable care by identifying how systemic inflammation affects cardiovascular outcomes,” said Anum Saeed, M.D., American Heart Association volunteer, member of the expert panel for the data challenge and assistant professor of medicine at the University of Pittsburgh. “We hope to spark discoveries that inform clinical practice as well as public health strategies through this innovative collaboration of data science researchers and clinicians.”

Through the Association’s Precision Medicine Platform, scientific researchers participating in the challenge will examine the specific role and mechanisms in which elevated levels of hsCRP contribute to the development of cardiovascular disease. Participants have the option of using multiple datasets provided by the American Heart Association and/or using their own data to investigate how inflammation — especially when influenced by social drivers of health, which are the conditions in which people are born and live — may increase the risk of heart disease.

The top three submissions will receive awards totaling $75,000, including a $40,000 first prize. Finalists will present their findings at the American Heart Association’s Scientific Sessions, with the goal of publishing results in peer-reviewed journals.

Funded in part by Novo Nordisk Inc., the challenge marks a strategic opportunity to identify solutions to, while elevating awareness about, inflammation’s overall impact on heart health.

For more information or to register for the challenge, visit pmp.heart.org/systemicinflammationdatachallenge.

Additional Resources:

###

 About the American Heart Association

The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public’s health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on heart.org, Facebook, X or by calling 1-800-AHA-USA1.   

For Media Inquiries: 214-706-1173

Michelle Rosenfeld: 214-706-1099; michelle.rosenfeld@heart.org  

For Public Inquiries: 1-800-AHA-USA1 (242-8721)

heart.org and stroke.org

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.